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Summary 
In order to investigate the possibility that, in the rat, some cerebral cortex 
somatostatin (SS) receptors may be localized presynaptically on the terminals of 
serotonergic neurons, serotonin [5-hydroxytryptamine, (5-HT)] neurons in the 
central nervous system were damaged with a local intracerebral injection of the 
serotonergic neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT). The injection of 5,7- 
DHT (11 /~g free base dissolved in 10 t~l of isotonic saline containing 0.01% 
ascorbic acid) in rats produced an reduction by about 74 % in frontoparietal cortical 
5-HT content at 1 and 3 weeks after injection. These changes were associated with 
a significant decrease by about 30 % in the total number of specific SS receptors 
in the frontoparietal cortex at both times studied without influencing the apparent 
affinity of the receptors. Together, these results suggest hat a portion of the 
frontoparietal cortex SS receptors may be localized presynaptically on the 
serotonergic nerve terminals. The 5,7-DHT did not affect SS-like immunoreactivity 
(SSLI) levels suggesting that SS and 5-HT are not colocalized within the same 
neuronal elements in the rat frontoparietal cortex. 
Somatostatin (SS) was the first growth hormone release inhibiting factor to be discovered 
(1). The highest concentrations were found in the hypothalamus (2), but SS has also been found 
widely throughout he central nervous system (3-6). It has been proposed as a central 
neurotransmitter and neuromodulator since it is highly concentrated within nerve endings (7), is 
released in vitro on depolarization i  a calcium-dependent manner (8), and it modulates and it is 
modulated by monoaminergic transmission (9-12). In this regard, SS was found to facilitate, in 
a dose-dependent manner, the electric,-or high K ÷, stimulated release of serotonin [5- 
hydroxytryptamine, (5-HT)] from rat cerebral cortex (13). In addition, SS has been shown to 
increase brain serotonergic tumover (14). These findings suggest that such actions are probably 
mediated through specific SS receptors present in the brain (15-18). To our knowledge it is 
unknown whether there are SS receptors located on serotonergic-containing erve terminals in the 
cerebral cortex. As an initial approach to examining the posibility that, in the rat, some cerebral 
cortex SS receptors may be presynaptically ocated on the terminals of serotonergic neurons, we 
studied the effects of administering 5,7-dihydroxytryptamine (5,7-DHT), which induces extensive 
axonal degeneration f central 5-HT neurons after intraventricular or intracerebral injection in the 
rat (19-21), on specific SS binding to membranes from rat frontoparietal cortex. This brain region 
was employed here because it contains ignificant amounts of SS (3-6), as well as SS receptors 
(15-18) as well as receiving serotonergic innervation (22). This study was done at 1 and 3 weeks 
after 5,7-DHT administration. SS- and 5-HT-like immunoreactivity n the frontoparietal cortex 
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of these rats has also been examined. 
Materials and Methods 
Chemicals 
Synthetic Tyr 11-SS and SS tetradecapeptide were purchased from Universal Biological Ltd 
(Cambridge, U.K.); 5,7-DHT, desmethyli mipramine (DMI), bacitracin and bovine serum albumin 
(BSA) (fraction V) from Sigma (St. Louis, Mo U.S.A.); and carrier-free Na125I (IMS 30, 100 
mCi/ml) from the Radiochemical Centre (Amersham, U.K.). The rabbit antibody used in the 
radioimmunoassay technique was purchased from the Radiochemical Centre (Amersham, Bucks, 
U.K.). This antiserum was raised in rabbits against SS-14 conjugated to bovine serum albumin 
and is specific for SS but it does not distinguish between SS-14, SS-25 and SS-28. All other 
chemicals were reagent grade. 
Experimental nimals 
Adult Wistar rats, initially weighing approximately 200 g, were maintained on a 12-hr 
light/12-hr dark cycle; with food and water ad libitum. The chemical destruction of ascending 
serotonergic neurons was accomplished under ether anesthesia, by local intracerebral injection of 
5,7-DHT (11/~g of free base in 10 ILl of isotonic saline containig 0.01% ascorbic acid to prevent 
oxidation of the 5,7-DHT), according to a modification of the method escribed by Bj6rklund et 
al (23). The injection of 5,7-DHT was carried out using a stainless teel cannula (outer diameter: 
0.21 mm; inner diameter 0.13 mm) acutely implanted at the following coordinates: A: 2.6 mm, 
L: 0.4 mm, H: 2.2 mm (24). In order to protect noradrenergic neurons from the neurotoxic 
action of 5,7-DHT, desmethylimipramine (DMI) (25 mg/kg intraperitoneally) was administered 
45 min before the injection of the neurotoxic agent (25). Control rats were treated identically 
except that no neurotoxin was injected. The rats were decapitated at 1 and 3 weeks after the 
injection. The brain was rapidly removed and frontoparietal cortex was dissected over ice 
according to the method of Glowinsky and Iverssen (26). 
Measurements of monoamines and SS 
To assess the destruction of serotonergic neurons in rats treated with the neurotoxin 5,7- 
DHT, as well as the protection of noradrenergic neurons by pretreatment with DMI, 
frontoparietal cortex 5-HT and noradrenaline (NA) contents of control and treated rats were 
measured by high-performance liquid chromatography (HPLC) with electrochemical detection 
(27). SS was extracted from the frontoparietal cortex following the method of Patel and Reichlin 
(28). SSLI content was measured by a modified specific radioimmunoassay method (28), with a 
sensitivity limit of 10 pg/ml. Protein concentration was estimated by the method of Lowry et al. 
(29) using bovine serum albumin as a standard. Separation of bound and free neuropeptide was 
accomplished by addition of 1 ml dextran coated charcoal (dextran 0.2 % w/v; charcoal 2% w/v). 
The dilution curve of the frontoparietal cortex was paralled to the standard curve. The intra- and 
inter-assay variation coefficients were 5,9% and 9,1%, respectively. 
Binding assay 
Tyr 11-SS was radioiodinated by the chloramine-T method (30). The tracer was purified 
in a Sephadex G-25 coarse column (lxl00) wich had been equilibrated with 0.1 M acetic acid 
containing bovine serum albumin 0.1% (w/v). Specific tracer radioactivity was about 380 Ci/g. 
Frontoparietal cortex membranes were prepared as described by Reubi et al (31). Proteins were 
assayed by the method of Lowry et al (29), with bovine serum albumin as a standard. Specific 
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SS binding was measured according to the modified method of Czernik and Petrack (32). The 
membranes (0.15 mg protein/ml) were incubated in 250 #1 of a medium containing 50 mM Tris- 
HC1 buffer (pH 7.5), 5mM MgCI2, 0.2% (w/v) bovine serum albumin and 0.1 mg/ml bacitracin 
with 250 pM 125I-Tyrll-ss either in the absence or in the presence of 0.01-10 nM unlabeled SS. 
After 60 min incubation at 30°C, the free radioligand was separated from the bound radioligand 
by centrifugation at 12000 g (Beckman microcentrifuge) for 1.5 min and the resultant pellet was 
counted in a Beckman gamma counter. Nonspecific binding, i.e., binding occurring in the 
presence of a high concentration (10 .7 M) of unlabelled SS, represented about 20% of the binding 
observed in the absence of native peptide and was subtracted from the total bound radioactivity 
in order to obtain the corresponding specific binding. The inactivation of 125I-Tyr11-SS in the 
incubation medium after exposure to membranes was studied by observing the ability of the 
peptide to rebind to fresh membranes (33). 
Data analysis 
Saturation curves were plotted according to the methods of Scatchard (34). Kd and Bmax 
were determined by linear regression analysis. The student's t test for unpaired variables was 
employed to asses differences between control and experimental groups. Results were given in 
all cases as the mean + SEM. 
Results 
Destruction of the ascending serotonergic pathways by the intracerebral injection of 5,7- 
DHT resulted in an approximately 74% depletion of 5-HT in the frontoparietal cortex at 1 and 
3 weeks after the drug treatment (Table I). No significant depletion of NA ocurred in the cortex 
of 5,7-DHT rats (90-95% of control values, data not shown). 
The administration of 5,7-DHT or DMI did not affects SSLI levels in the frontoparietal 
cortex in comparison with the control group at either time studied (92-98 % of control values, data 
not shown). 
TABLE I 
Effect of 5,7-dihydroxytryptamine (5,7-DHT) and desmethylimipramine (DMI) on the levels of 
serotonin [5-hydroxytryptamine, (5-HT)] in the frontoparietal cortex of the rat at one and three 
weeks after administration. 
Frontoparietal cortex 
5-HT 
Groups 1 week 3 weeks 
Control 410.1 _ 12.5 425.6  _ 13.8 
DMI+5,7-DHT 105 + 10.2 * 110 _ 9.8 * 
The results are expressed as means + S.E.M. in ng of 5-HT/g wet weight of tissue of six rats 
in each group. Statistical comparison versus controls: *p < 0.0001. 
Frontopafietal cortex membranes from the experimental groups bound 125I-Tyrl 1-SS in a 
time-dependent fashion; an apparent equilibrium was observed between 50 and 120 min at 30°C 
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(data not shown). All subsequent binding experiments were therefore conducted at 30°C for 60 
min. 
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FIG.1 
Competitive inhibition of specific 12SI-TyrH-somatostatin (12SI-TyrtLSS, 250 pM) 
binding by unlabeled SS to frontoparietal cortex membranes. Membranes (0.15 mg 
protein/ml) were incubated for 60 rain at 30°C in the presence of 250 pM 1251- 
TyrH-SS and increasing concentrations of native peptide. Points correspond to 
control animals (O) and 5,7-DHT-treated rats at 1 (zx) and 3 (o) weeks after 5,7- 
DHT injection. Each point is the mean of five rats in each group. 
Peptide degradation was determined in all the preparations to rule out the possibility of 
different SS degrading activities which might have affected the interpretation of the results. 
Membranes from the frontoparietal cortex showed a similar peptide degradation capacity and the 
values varied by no more than 10% among all the experimental groups. 
Increasing concentrations of unlabeled SS competitively inhibited the specific binding of 
]2SI-Tyr I LSS to rat frontoparietal cortex membranes in the preparations from both control and 5,7- 
DHT-treated rats. At 1 and 3 weeks after the 5,7-DHT injection adecrease in the specific binding 
of the ~2SI-Tyr"-SS to membranes from the frontoparietal cortex was observed (Fig. 1). 
Sctchard plots of the binding of tracer to membranes from frontoparietal cortex indicated 
that intracerebral injection of 5,7-DHT was associated with a decrease in the number of SS 
receptors in the frontoparietal cortex without affecting the affinity constant at either time studied 
(Fig. 2 and Table II). DMI alone had no observable ffect on the binding of ]2SI-Tyrn-SS to 
membranes from frontoparietal cortex (Table II). 
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FIG.2 
Scatchard plots of specific 125-I-TyrU-somatostatin (125-I-Tyr11-SS, 250 pM) 
binding to frontoparietal cortex membranes (0.15 mg protein/ml) from controls 
( • ) and 5,7-DHT-treated rats 1 ( lX ) and 3 ( O ) weeks following 5,7-DHT 
injection. Each point is the mean of five rats in each group. The corresponding 
equilibrium binding parameters are incluided in Table II. 
TABLE II 
Effect of 5,7-dihydroxytryptamine (5,7-DHT) and desmethylimipramine (DMI) on equilibrium 
parameters of 125I-Tyrl 1-somatostatin (125I-Tyr1LSS) binding to frontoparietal cortex membranes. 
Frontoparietal cortex 
Groups 1 week 3 weeks 
Control 
Kd 0.46 _ 0.05 0.42 _+ 0.06 
Bmax 587 _+ 28 540 + 23 
DMI+5,7-DHT 
Kd 0.42 _+ 0.04 0.48 -t- 0.07 
Bmax 418 _ 28"  381 +_ 21"*  
DMI 
Kd 0.45 _ 0.03 0.43 _ 0.05 
Bmax 553 _ 25 565 + 27 
Kd is the dissociation constant, nM; Bmax is the binding capacity, from fentomoles of SS bound 
per mg protein. Each value is the mean _+ S.E.M. of five rats in each group. Statistical 
comparison versus controls: *p < 0.003 **p < 0.001. 
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Discussion 
The injection of 5,7-DHT severely decreased the level of 5-HT (by about 74%) in the rat 
frontoparietal cortex while leaving the NA contents essentially unchanged in agreement with 
previously published values (19-21). Thus, the innervation of this brain region by 5-HT axons 
was nearly abolished by 5,7-DHT, whereas the NA axons remained essentially intact. 
The SSLI content in the frontoparietal cortex in the control rats was similar to those 
previously reported by others (35-36). The treatment with 5,7-DHT did not affect SSLI levels in 
the frontoparietal cortex in comparison with the control group at either time studied. This suggests 
that SS and 5-HT are not colocalized in the same neuronal elements in the rat frontoparietal 
cortex. 
The Scatchard analysis of the stechiometric data suggest he existence of only one type 
of SS receptor. This finding agrees with some studies in rat brain membranes (16,32,35) but 
differs from other more recent data (18,37). It is conceivable that the use of small SS analogues 
(38) or their labelling with different isotopes (18) might explain this difference. 
The fact that the injection of 5,7-DHT decreased the level of 5-HT (by about 74%) and 
the number of SS receptors (by about 30%) in the frontoparietal cortex, together with the 
evidence that SS exerts a presynaptic control on the release (13) and turnover (14) of cortical 5- 
HT, suggests that some of the frontoparietal cortex SS receptors could be located on the 
serotonergic neuronal terminals. The difference in magnitude between 5-HT depletion and the 
decrease in SS receptors also raises the possibility that the receptors could be present on neuronal 
terminal membrane 'ghosts' that remain after 5,7-DHT treatment. Apart from presynaptic 
receptors on 5-HT afferents, an alternative xplanation for the loss of SS receptors is the 
possibility of transsynaptic effects on receptor expression. 
The presence of SS receptors on serotonergic neurons in the frontoparietal cortex might 
provide a basis for the better understanding of the basic mechanism of numerous complex cerebral 
activities such as learning, sleep and mood, (6,38) which are thought o be involved in both 
neuronal systems. 
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